FDA Approves New Cystic Fibrosis Treatment

cystic-fibrosis-foundation-logo-e1479836089698Trikafta is the first triple combination (elexacaftor/tezacaftor/ivacaftor) drug therapy approved by the FDA to treat cystic fibrosis. Trikafta is approved for patients 12 and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.  The F508del mutation is the most common mutation of over 2,000 mutations of the CFTR gene. According to the FDA, this covers around 90% of U.S. cystic fibrosis patients. read more at https://www.cff.org/News/News-Archive/2019/CF-Foundation-Celebrates-FDA-Approval-of-Triple-Combination/